IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
107 hedge funds and large institutions have $1.11B invested in IGM Biosciences in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 32 reducing their positions, and 13 closing their positions.
543% more call options, than puts
Call options by funds: $18.7M | Put options by funds: $2.91M
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
2.1% more ownership
Funds ownership: 63.83% → 65.94% (+2.1%)
2% more funds holding
Funds holding: 105 → 107 (+2)
9% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
18% less capital invested
Capital invested by funds: $1.36B → $1.11B (-$248M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28.4M |
| 2 |
AG
Artal Group
Luxembourg
|
+$19.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.65M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.29M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$5.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$13.5M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$12.6M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$10.2M |
| 4 |
Alkeon Capital Management
New York
|
-$7.85M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.66M |
IGMS Hedge Fund Activity: Q3 2021 in Review
107 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q3 2021, worth a combined $1.11B — down 18% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IGMS positions and 13 closed out — a net gain of 3 holders — while 35 added to existing stakes and 32 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $28.4M. The largest seller was Woodline Partners, cutting an estimated $13.5M.
- 107 institutional investors held IGM Biosciences (IGMS) as of Q3 2021, up from 105 in Q2 2021.
- Funds reported $1.11B of IGM Biosciences stock for Q3 2021, down 18% quarter-over-quarter.
- 16 funds opened new IGM Biosciences positions in Q3 2021 and 13 closed out, a net change of +3 holders.
- The largest IGM Biosciences buyer in Q3 2021 was T. Rowe Price Associates, an estimated $28.4M added.
- The largest IGM Biosciences seller in Q3 2021 was Woodline Partners, an estimated $13.5M sold.
Based on aggregated 13F filings for Q3 2021.